- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT07549516
Исследование переносимости, безопасности и эффективности ациминиба у пациентов с филадельфийской хромосомоположительной хронической миелодидной лейкемии в хронической фазе в Германии (ASC2ADHERE)
Неинтервенционное исследование переносимости, безопасности и эффективности асциминиба у пациентов с впервые диагностированным и ранее леченным хроническим миелоидным лейкозом с положительной филадельфийской хромосомой в хронической фазе в Германии — исследование ASC2ADHERE
The aim of this study is to assess the real-world effectiveness of asciminib in Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP) patients who were either newly diagnosed or previously treated with one ATP-competitive tyrosine kinase inhibitor (TKI).
Обзор исследования
Статус
Условия
Тип исследования
Регистрация (Оцененный)
Контакты и местонахождение
Контакты исследования
- Имя: Novartis Pharmaceuticals
- Номер телефона: +41613241111
- Электронная почта: novartis.email@novartis.com
Учебное резервное копирование контактов
- Имя: Novartis Pharmaceuticals
Места учебы
-
-
-
Amberg, Германия, 92224
- Рекрутинг
- Novartis Investigative Site
-
Bad Friedrichshall, Германия, 74177
- Рекрутинг
- Novartis Investigative Site
-
Bad Liebenwerda, Германия, 04924
- Рекрутинг
- Novartis Investigative Site
-
Bad Saarow, Германия, 15526
- Рекрутинг
- Novartis Investigative Site
-
Berlin, Германия, 10437
- Рекрутинг
- Novartis Investigative Site
-
Berlin, Германия, 10365
- Рекрутинг
- Novartis Investigative Site
-
Berlin, Германия, 12552
- Рекрутинг
- Novartis Investigative Site
-
Berlin, Германия, 10559
- Рекрутинг
- Novartis Investigative Site
-
Berlin, Германия, 12487
- Рекрутинг
- Novartis Investigative Site
-
Bremerhaven, Германия, 27568
- Рекрутинг
- Novartis Investigative Site
-
Buchholz Nordheide, Германия, 21244
- Рекрутинг
- Novartis Investigative Site
-
Cottbus, Германия, 03046
- Рекрутинг
- Novartis Investigative Site
-
Deggendorf, Германия, 94469
- Рекрутинг
- Novartis Investigative Site
-
Detmold, Германия, 32756
- Рекрутинг
- Novartis Investigative Site
-
Dorfen, Германия, 84405
- Рекрутинг
- Novartis Investigative Site
-
Dortmund, Германия, 44263
- Рекрутинг
- Novartis Investigative Site
-
Dresden, Германия, 01307
- Рекрутинг
- Novartis Investigative Site
-
Dresden, Германия, 01127
- Рекрутинг
- Novartis Investigative Site
-
Düren, Германия, 52353
- Рекрутинг
- Novartis Investigative Site
-
Erfurt, Германия, 99085
- Рекрутинг
- Novartis Investigative Site
-
Erfurt, Германия, 99084
- Рекрутинг
- Novartis Investigative Site
-
Eschweiler, Германия, 52249
- Рекрутинг
- Novartis Investigative Site
-
Göttingen, Германия, 37073
- Рекрутинг
- Novartis Investigative Site
-
Hanover, Германия, 30161
- Рекрутинг
- Novartis Investigative Site
-
Hanover, Германия, 30625
- Рекрутинг
- Novartis Investigative Site
-
Hildesheim, Германия, 31135
- Рекрутинг
- Novartis Investigative Site
-
Kiel, Германия, 24105
- Рекрутинг
- Novartis Investigative Site
-
Leipzig, Германия, 04103
- Рекрутинг
- Novartis Investigative Site
-
Leverkusen, Германия, 51375
- Рекрутинг
- Novartis Investigative Site
-
Mutlangen, Германия, 73557
- Рекрутинг
- Novartis Investigative Site
-
Naunhof, Германия, 04683
- Рекрутинг
- Novartis Investigative Site
-
Neuss, Германия, 41462
- Рекрутинг
- Novartis Investigative Site
-
Offenburg, Германия, 77654
- Рекрутинг
- Novartis Investigative Site
-
Oldenburg, Германия, 26121
- Рекрутинг
- Novartis Investigative Site
-
Parchim, Германия, 19370
- Рекрутинг
- Novartis Investigative Site
-
Potsdam, Германия, 14467
- Рекрутинг
- Novartis Investigative Site
-
Potsdam, Германия, 14482
- Рекрутинг
- Novartis Investigative Site
-
Schorndorf, Германия, 73614
- Рекрутинг
- Novartis Investigative Site
-
Schwetzingen, Германия, 68723
- Рекрутинг
- Novartis Investigative Site
-
Soest, Германия, 59494
- Рекрутинг
- Novartis Investigative Site
-
Stade, Германия, 21680
- Рекрутинг
- Novartis Investigative Site
-
Torgau, Германия, 04860
- Рекрутинг
- Novartis Investigative Site
-
Ulm, Германия, 89081
- Рекрутинг
- Novartis Investigative Site
-
Wetzlar, Германия, 35578
- Рекрутинг
- Novartis Investigative Site
-
-
Baden-Wurttemberg
-
Baden-Baden, Baden-Wurttemberg, Германия, 76532
- Рекрутинг
- Novartis Investigative Site
-
Heidenheim, Baden-Wurttemberg, Германия, 89522
- Рекрутинг
- Novartis Investigative Site
-
Schwäbisch Hall, Baden-Wurttemberg, Германия, 74523
- Рекрутинг
- Novartis Investigative Site
-
Winnenden, Baden-Wurttemberg, Германия, 71364
- Рекрутинг
- Novartis Investigative Site
-
-
Bavaria
-
Aschaffenburg, Bavaria, Германия, 63739
- Рекрутинг
- Novartis Investigative Site
-
Augsburg, Bavaria, Германия, 86152
- Рекрутинг
- Novartis Investigative Site
-
Donauwörth, Bavaria, Германия, 86609
- Рекрутинг
- Novartis Investigative Site
-
Herrsching am Ammersee, Bavaria, Германия, 82211
- Рекрутинг
- Novartis Investigative Site
-
Kempten (Allgäu), Bavaria, Германия, 87439
- Рекрутинг
- Novartis Investigative Site
-
Landsberg am Lech, Bavaria, Германия, 86899
- Рекрутинг
- Novartis Investigative Site
-
Munich, Bavaria, Германия, 81241
- Рекрутинг
- Novartis Investigative Site
-
Munich, Bavaria, Германия, 81377
- Рекрутинг
- Novartis Investigative Site
-
Regensburg, Bavaria, Германия, 93053
- Рекрутинг
- Novartis Investigative Site
-
-
Free Hanseatic City of Bremen
-
Bremerhaven, Free Hanseatic City of Bremen, Германия, 27576
- Рекрутинг
- Novartis Investigative Site
-
-
Hesse
-
Kassel, Hesse, Германия, 34125
- Рекрутинг
- Novartis Investigative Site
-
Offenbach, Hesse, Германия, 63065
- Рекрутинг
- Novartis Investigative Site
-
-
Lower Saxony
-
Goslar, Lower Saxony, Германия, 38642
- Рекрутинг
- Novartis Investigative Site
-
Rotenburg (Wümme), Lower Saxony, Германия, 27356
- Рекрутинг
- Novartis Investigative Site
-
Twistringen, Lower Saxony, Германия, 27239
- Рекрутинг
- Novartis Investigative Site
-
-
North Rhine-Westphalia
-
Cologne, North Rhine-Westphalia, Германия, 50674
- Рекрутинг
- Novartis Investigative Site
-
Cologne, North Rhine-Westphalia, Германия, 50677
- Рекрутинг
- Novartis Investigative Site
-
Cologne, North Rhine-Westphalia, Германия, 51103
- Рекрутинг
- Novartis Investigative Site
-
Solingen, North Rhine-Westphalia, Германия, 42653
- Рекрутинг
- Novartis Investigative Site
-
Wesel, North Rhine-Westphalia, Германия, 46483
- Рекрутинг
- Novartis Investigative Site
-
-
Saxony
-
Zittau, Saxony, Германия, 02763
- Рекрутинг
- Novartis Investigative Site
-
-
Saxony-Anhalt
-
Halle, Saxony-Anhalt, Германия, 06110
- Рекрутинг
- Novartis Investigative Site
-
Merseburg, Saxony-Anhalt, Германия, 06217
- Рекрутинг
- Novartis Investigative Site
-
-
Schleswig-Holstein
-
Oldenburg in Holstein, Schleswig-Holstein, Германия, 23758
- Рекрутинг
- Novartis Investigative Site
-
-
Thuringia
-
Altenburg, Thuringia, Германия, 04600
- Рекрутинг
- Novartis Investigative Site
-
Saalfeld, Thuringia, Германия, 07318
- Рекрутинг
- Novartis Investigative Site
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Метод выборки
Исследуемая популяция
Adult Ph+ CML-CP patients, either newly diagnosed or previously treated with one ATP-competitive TKI, who initiate TKI treatment as recommended by the treating physician in a hematology center in Germany.
Описание
Inclusion criteria:
- Written informed consent must be obtained before participation in the study/prior to any study-related documentation.
- Adult patients (≥18 years of age) with a confirmed diagnosis of Ph+ CML-CP. The presence of the Philadelphia chromosome may alternatively be confirmed by molecular detection of a BCR::ABL1 fusion gene/transcript (e.g., by reverse transcription polymerase chain reaction (RT-PCR)), in accordance with the World Health Organization (WHO) 2022 classification.
- Patients who are either newly diagnosed or have received treatment with exactly one prior TKI. Prior TKI treatment is only permitted for patients in the Asciminib Cohort. Patients in the comparator cohorts (imatinib, dasatinib, bosutinib, nilotinib) must be newly diagnosed and must not have received any prior TKI treatment.
- Patients for whom the treating physician has made a clinical decision to initiate treatment with asciminib or another TKI (imatinib, dasatinib, bosutinib, nilotinib) as part of routine care. The clinical decision for treatment must have been made prior to enrollment. Treatment must not have started more than 14 days before study inclusion, and treatment may also begin after baseline assessment.
- Patients willing to participate in routine follow-up visits and complete patient-reported outcome questionnaires over the course of the study.
Exclusion criteria:
-
Patients with contraindications to their respective chronic myeloid leukemia (CML) treatment as per the applicable Summary of Product Characteristics (SmPC) and relevant national treatment guidelines (e.g. Onkopedia CML), as well as additional disease- or treatment-related characteristics associated with distinct clinical scenarios that differ from the intended study population, including situations with specific treatment requirements or limited comparability, in which reliable interpretation of study outcomes may not be feasible, including the following asciminib specific considerations:
-
In first- or second-line treatment: presence of BCR::ABL1 fusion transcripts lacking exon a2 (e.g. e13a3, e14a3, e1a3).
-
In second-line treatment:
- known BCR::ABL1 mutations associated with partial or complete resistance to asciminib (e.g. M244V, F359I/V/C).
- presence of the BCR::ABL1 T315I mutation, regardless of eligibility for treatment according to SmPC (e.g., specific indication and dosing regimens).
-
-
Patients receiving or planned to receive asciminib or other TKIs outside the approved label (off-label use), including use in unapproved dosing regimens or frequency not covered by the respective SmPC.
-
Patients currently participating in an interventional clinical trial.
-
Patients unable or unwilling to provide written informed consent.
-
Patients who are unable to reliably complete patient-reported outcome questionnaires due to cognitive or language limitations relevant to the study assessments.
-
Patients for whom long-term follow-up is not feasible due to expected relocation or other logistical constraints.
-
The restriction to a maximum of one prior ATP-competitive TKI applies exclusively to patients treated with asciminib. Patients in the comparator cohorts (imatinib, dasatinib, bosutinib, nilotinib) must be TKI-naïve and are included at the start of their first-line TKI therapy and are not eligible if they have received any prior TKI treatment.
Учебный план
Как устроено исследование?
Детали дизайна
- Наблюдательные модели: COHORT
- Временные перспективы: PROSPECTIVE
Когорты и вмешательства
Группа / когорта |
|---|
|
Asciminib Cohort
Adult patients with Ph+ CML-CP, either newly diagnosed or previously treated with one TKI, who are treated with asciminib. |
|
Imatinib Cohort
Adult patients newly diagnosed with Ph+ CML-CP treated with imatinib who have not received any prior TKI treatment. |
|
Second-generation TKI Cohort
Adult patients newly diagnosed with Ph+ CML-CP treated with dasatinib, bosutinib, or nilotinib who have not received any prior TKI treatment. |
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Percentage of Patients With Major Molecular Response (MMR) at 12 Months
Временное ограничение: Month 12
|
MMR is defined as a BCR::ABL1 level ≤ 0.1% according to the International Scale (IS). |
Month 12
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Доля пациентов по причине решения о лечении ИТК, зафиксированной лечащим врачом ⬆
Временное ограничение: Исходный уровень
|
Исходный уровень
|
|
|
Доля пациентов со снижением дозы по причине снижения дозы
Временное ограничение: 3, 6, 9, 12, 15, 18, 21 и 24 месяца
|
3, 6, 9, 12, 15, 18, 21 и 24 месяца
|
|
|
Доля пациентов с перерывами в лечении по причине перерыва
Временное ограничение: 3, 6, 9, 12, 15, 18, 21 и 24 месяца
|
3, 6, 9, 12, 15, 18, 21 и 24 месяца
|
|
|
Процент пациентов, прекративших лечение по причине прекращения терапии
Временное ограничение: 3, 6, 9, 12, 15, 18, 21 и 24 месяца
|
3, 6, 9, 12, 15, 18, 21 и 24 месяца
|
|
|
Time to Treatment Discontinuation
Временное ограничение: 3, 6, 9, 12, 15, 18, 21 и 24 месяца
|
3, 6, 9, 12, 15, 18, 21 и 24 месяца
|
|
|
Время до перерыва в лечении
Временное ограничение: 3, 6, 9, 12, 15, 18, 21 и 24 месяца
|
3, 6, 9, 12, 15, 18, 21 и 24 месяца
|
|
|
Время до снижения дозы
Временное ограничение: 3, 6, 9, 12, 15, 18, 21 и 24 месяца
|
3, 6, 9, 12, 15, 18, 21 и 24 месяца
|
|
|
Время до прекращения лечения из-за нежелательных явлений (ВПЛНЯ)
Временное ограничение: 3, 6, 9, 12, 15, 18, 21 и 24 месяца
|
3, 6, 9, 12, 15, 18, 21 и 24 месяца
|
|
|
Percentage of Patients by Clinical Characteristic
Временное ограничение: Baseline
|
Characteristics include, but are not limited to, detection of Philadelphia chromosome or BCR::ABL1 transcript, prior treatment, and Eastern Cooperative Oncology Group (ECOG) performance status. |
Baseline
|
|
Percentage of Patients With Early Molecular Response (EMR) at 3 Months
Временное ограничение: Month 3
|
EMR is defined as BCR::ABL1 ≤10% IS. |
Month 3
|
|
Percentage of Patients With Molecular Response 2 (MR2)
Временное ограничение: 3, 6, 9, 12, 15, 18, 21, and 24 months
|
MR2 is defined as BCR::ABL1 ≤1% IS. |
3, 6, 9, 12, 15, 18, 21, and 24 months
|
|
Percentage of Patients With MMR
Временное ограничение: 3, 6, 9, 15, 18, 21, and 24 months
|
MMR is defined as BCR::ABL1 ≤0.1% IS. |
3, 6, 9, 15, 18, 21, and 24 months
|
|
Percentage of Patients With Deep Molecular Response: MR4.0
Временное ограничение: 3, 6, 9, 12, 15, 18, 21, and 24 months
|
Deep Molecular Response (MR4.0): ≤0.01% BCR::ABL1 IS and Reference gene copies >10,000 ABL1 or >24,000 GUSB. |
3, 6, 9, 12, 15, 18, 21, and 24 months
|
|
Percentage of Patients With Deep Molecular Response: MR4.5
Временное ограничение: 3, 6, 9, 12, 15, 18, 21, and 24 months
|
Deep Molecular Response (MR4.5): ≤0.0032% BCR::ABL1 IS and Reference gene copies >32,000 ABL1 or >77,000 GUSB. |
3, 6, 9, 12, 15, 18, 21, and 24 months
|
|
Percentage of Patients With Deep Molecular Response: MR5
Временное ограничение: 3, 6, 9, 12, 15, 18, 21, and 24 months
|
Deep Molecular Response (MR5): ≤0.001% BCR::ABL1 IS and Reference gene copies >100,000 ABL1 or >240,000 GUSB. |
3, 6, 9, 12, 15, 18, 21, and 24 months
|
|
Medication Adherence Report Scale (MARS-5) Score
Временное ограничение: 3, 6, 9, 12, 15, 18, 21, and 24 months
|
The MARS-5 questionnaire is a validated self-report questionnaire developed to assess patient adherence to prescribed medication, focusing on both intentional and unintentional non-adherence. It consists of 5 items, each rated on a 5-point Likert Scale from 0 (always) to 5 (never). The total score ranges from 5 to 25, with higher scores indicating better adherence to treatment. |
3, 6, 9, 12, 15, 18, 21, and 24 months
|
|
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) Score
Временное ограничение: 3, 6, 9, 12, 15, 18, 21, and 24 months
|
The EORTC QLQ-C30 contains 30 questions answered by the patient. There are 9 multiple-item scales: 5 scales that assess aspects of functioning (physical, role functioning, cognitive, emotional, and social); 3 symptom scales (fatigue, pain, and nausea and vomiting); and a global health status/Quality of Life (QOL) scale. There are 5 single-item measures assessing additional symptoms (i.e., dyspnea, loss of appetite, insomnia, constipation, and diarrhea) and a single item concerning perceived financial impact of the disease. All but 2 questions have 4-point scales ranging from "Not at all" to "Very much." The 2 questions concerning global health status/QOL have 7-point scales with ratings ranging from "Very poor" to "Excellent." For each of the 14 domains, final scores are transformed such that they range from 0-100, where higher scores indicate improvement. |
3, 6, 9, 12, 15, 18, 21, and 24 months
|
|
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for CML (EORTC QLQ-CML24) Score
Временное ограничение: 3, 6, 9, 12, 15, 18, 21, and 24 months
|
The EORTC QLQ-CML24 was designed to supplement the QLQ-C30 - the QLQ-CML24 is not a stand-alone instrument but is to be used in conjunction with the QLQ-C30. The EORTC QLQ-CML24 is composed of 4 multi-item scales and 2 single-item scales. The module consists of 24 items assessing symptom burden (13 items), impact on worry/mood (4 items), impact on daily life (3 items), satisfaction with care and information (2 items) body image problems (1 item) and satisfaction with social life (1 item). The items are measured on 4 levels: 1=not at all, 2=a little, 3=quite a bit, 4=very much. For each domain, scores are averaged and transformed to 0 to 100. A higher score in symptom burden, impact on worry/mood, impact on daily life, and body image problems domains indicates a worse outcome. A higher score in satisfaction with social life and satisfaction with care and information domains indicates a higher level of satisfaction. |
3, 6, 9, 12, 15, 18, 21, and 24 months
|
|
Work Productivity and Activity Impairment - General Health (WPAI-GH) Score
Временное ограничение: 3, 6, 9, 12, 15, 18, 21, and 24 months
|
The WPAI-GH is a patient-reported 6 item questionnaire which addresses absenteeism, presenteeism, overall work productivity loss, and activity impairment for the 7 days prior to the assessment. Work productivity and activity impairment outcomes are presented as impairment percentages ranging from 0 to 100 with a higher percentage indicating greater impairment and less productivity. |
3, 6, 9, 12, 15, 18, 21, and 24 months
|
Соавторы и исследователи
Спонсор
Следователи
- Директор по исследованиям: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Оцененный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Дополнительные соответствующие термины MeSH
- Патологические процессы
- Новообразования
- Хроническое заболевание
- Атрибуты болезни
- Новообразования по гистологическому типу
- Гематологические заболевания
- Лейкоз, миелоидный
- Заболевания костного мозга
- Лейкемия
- Миелопролиферативные заболевания
- Патологические состояния, признаки и симптомы
- Гемики и лимфатические заболевания
- Лейкоз, миелогенный, хронический, BCR-ABL положительный
Другие идентификационные номера исследования
- CABL001J1DE02
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .